Medicinal Products

Vaxzevria

Name Vaxzevria
Former Name COVID-19 Vaccine AstraZeneca
Active Substance adenovirus čimpanze koji kodira glikoprotein šiljka virusa SARS-CoV-2 (ChAdOx1-S)

Prescription na recept
Type of prescription neponovljivi recept
Distribution u ljekarni
ATC Code J07BX03
Medicinal product marketed in the Croatia Da

Note

The medicinal product has been authorised via centralised procedure in all Member States of the European Union based on the European Medicines Agency's expert opinion. Additional information on the medicinal product can be found under the following link:https://www.ema.europa.eu/en/medicines/human/EPAR/covid-19-vaccine-astrazeneca

The marketing authorisation has been granted by the European Commission. All marketing authorisations of the European Commission can be found under the following link: http://ec.europa.eu/health/documents/community-register/html/index_en.htm

Direct Healthcare Professional Communication

Name Date Download
Pismo zdravstvenim radnicima o riziku od trombocitopenije (uključujući imunosnu trombocitopeniju) sa ili bez krvarenja kod primjene cjepiva Vaxzevria (ranijeg naziva COVID-19 Vaccine AstraZeneca) 13.10.2021 AstraZeneca AB
Pismo zdravstvenim radnicima o kontraindikaciji primjene cjepiva Vaxzevria (ranijeg naziva COVID-19 Vaccine AstraZeneca) u osoba koje su prethodno imale sindrom kapilarnog curenja 23.06.2021 AstraZeneca AB
Pismo zdravstvenim radnicima o povezanosti primjene cjepiva Vaxzevria (ranijeg naziva COVID-19 Vaccine AstraZeneca) i pojave tromboze u kombinaciji s trombocitopenijom - 2.6.2021. 02.06.2021 AstraZeneca AB
Pismo zdravstvenim radnicima o povezanosti primjene cjepiva Vaxzevria (ranijeg naziva COVID-19 Vaccine AstraZeneca) i pojave tromboze u kombinaciji s trombocitopenijom 14.04.2021 AstraZeneca AB
Pismo zdravstvenim radnicima o riziku od trombocitopenije i poremećaja zgrušavanja krvi za cjepivo Vaxzevria (COVID-19 Vaccine AstraZeneca) 24.03.2021 AstraZeneca AB
Back